| 发明名称 | Compounds and methods of modulating angiogenesis | ||
| 摘要 | A pharmaceutical composition includes a synthetic peptide consisting of about 10 to about 50 amino acids and having an amino acid sequence substantially homologous to consecutive amino acids of a portion of the cytoplasmic domain of at least one of αvβ3 integrin or VEGFR2 that includes a tyrosine residue, the amino acid sequence of the peptide including a phosphorylated tyrosine residue or a γ-carboxyglutamic acid residue that is substituted for a corresponding tyrosine residue of the portion of the cytoplasmic domain of αvβ3 integrin or VEGFR2. | ||
| 申请公布号 | US9592269(B2) | 申请公布日期 | 2017.03.14 |
| 申请号 | US201514937289 | 申请日期 | 2015.11.10 |
| 申请人 | The Cleveland Clinic Foundation | 发明人 | Byzova Tatiana;Mahabaleshwar Ganapati H.;Feng Weiyi |
| 分类号 | A61K38/17;A61K38/18;A61K38/08;A61K38/10 | 主分类号 | A61K38/17 |
| 代理机构 | Tarolli, Sundheim, Covell & Tummino LLP | 代理人 | Tarolli, Sundheim, Covell & Tummino LLP |
| 主权项 | 1. A pharmaceutical composition comprising a synthetic peptide, the peptide consisting of about 10 to about 50 amino acids and comprising an amino acid sequence substantially homologous to a portion of VEGFR2, wherein the amino acid sequence is selected from the group consisting of: SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO:23, and SEQ ID NO: 24, the peptide inhibits interaction of αvβ3 integrin with VEGFR2. | ||
| 地址 | Cleveland OH US | ||